BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CEO Neil Kumar sold 40,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $67.46, for a total transaction of $2,698,400.00. Following the sale, the chief executive officer directly owned 535,686 shares in the company, valued at $36,137,377.56. This trade represents a 6.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Neil Kumar also recently made the following trade(s):
- On Thursday, May 21st, Neil Kumar sold 26,103 shares of BridgeBio Pharma stock. The stock was sold at an average price of $69.44, for a total transaction of $1,812,592.32.
- On Thursday, May 7th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $67.90, for a total transaction of $2,716,000.00.
- On Thursday, April 9th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.62, for a total transaction of $2,984,800.00.
- On Thursday, March 12th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $68.73, for a total transaction of $2,749,200.00.
BridgeBio Pharma Stock Down 0.4%
Shares of NASDAQ:BBIO traded down $0.24 on Monday, reaching $67.37. 1,751,907 shares of the company’s stock were exchanged, compared to its average volume of 2,809,104. The firm has a market capitalization of $13.20 billion, a price-to-earnings ratio of -18.01 and a beta of 0.97. BridgeBio Pharma, Inc. has a fifty-two week low of $38.57 and a fifty-two week high of $84.94. The business’s 50-day moving average is $70.70 and its two-hundred day moving average is $72.11.
Institutional Investors Weigh In On BridgeBio Pharma
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in BridgeBio Pharma by 2.1% during the third quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock worth $874,257,000 after purchasing an additional 347,074 shares in the last quarter. Janus Henderson Group PLC raised its holdings in BridgeBio Pharma by 19.8% during the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after purchasing an additional 2,178,556 shares in the last quarter. Farallon Capital Management LLC raised its holdings in BridgeBio Pharma by 9.8% during the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after purchasing an additional 806,463 shares in the last quarter. Aisling Capital Management LP raised its holdings in BridgeBio Pharma by 0.4% during the third quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock worth $316,294,000 after purchasing an additional 21,486 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in BridgeBio Pharma by 23.0% during the fourth quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after purchasing an additional 902,648 shares in the last quarter. Institutional investors own 99.85% of the company’s stock.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Mizuho reaffirmed an “outperform” rating and issued a $106.00 price objective on shares of BridgeBio Pharma in a report on Tuesday, April 28th. Leerink Partners reissued an “outperform” rating and issued a $98.00 price objective on shares of BridgeBio Pharma in a report on Thursday, March 12th. Barclays reissued an “overweight” rating on shares of BridgeBio Pharma in a report on Tuesday, March 10th. Citigroup started coverage on BridgeBio Pharma in a research report on Tuesday, May 19th. They set a “neutral” rating and a $82.00 price target for the company. Finally, William Blair started coverage on BridgeBio Pharma in a research note on Tuesday, March 10th. They issued an “outperform” rating for the company. Twenty-three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average target price of $89.59.
View Our Latest Research Report on BridgeBio Pharma
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Stories
- Five stocks we like better than BridgeBio Pharma
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
